Actionable news
0
All posts from Actionable news
Actionable news in AUPH: AURINIA PHARMACEUTICALS INC,

SCHEDULE 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

(Amendment No. 1)

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED

PURSUANT TO 240.13d-2(a)

Under the Securities Exchange Act of 1934

Aurinia Pharmaceuticals Inc.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

05156V102

(CUSIP Number)

ILJIN Life Science Co., Ltd.

(Dohwa-dong), 45 Mapo-daero, Mapo-gu

Seoul, Korea 121-716

+82-2-707-9742

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 28, 2016

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.

Name of reporting person

ILJIN Life Science Co., Ltd.

2.

Check the appropriate box if a member of a group

(a) ¨ (b) ¨

3.

SEC use only

4.

Source of funds

WC

5.

Check box if disclosure of legal proceedings is required pursuant to Item 2(e) or 2(f) ¨

6.

Citizenship or place of organization

South Korea

Number of

shares

beneficially

owned by

each

reporting

person

with

7.

Sole voting power

0

8.

Shared voting power

4,732,138*

9.

Sole dispositive power

0

10.

Shared dispositive power

4,732,138*

11.

Aggregate amount beneficially owned by each reporting person

4,732,138*

12.

Check box if the aggregate amount in Row (11) excludes certain shares ¨

13.

Percent of class represented by amount in Row (11)

8.94%**

14.

Type of reporting person

CO

* Consists of: (i) 4,586,605 common shares (“Common Shares”) of Aurinia Pharmaceuticals Inc. (the “Issuer”) held by ILJIN Life Science Co., Ltd. (“ILJIN Life Science”); and (ii) 145,533 Common Shares issuable to ILJIN Life Science upon the exercise of outstanding warrants that are exercisable within 60 days.
** Based on: (i) 52,808,235 Common Shares issued and outstanding as of December 28, 2016, as reported to the Reporting Persons by the Issuer, plus (ii) 145,533 Common Shares underlying warrants held by ILJIN Life Science that are exercisable within 60 days, which are treated as issued and outstanding only for the purpose of computing the percentage ownership of ILJIN Life Science pursuant to Rule 13d-3(d)(1)(i) under the Act.
1.

Name of reporting person

ILJIN SNT Co., Ltd.

2.

Check the appropriate box if a member of a group

(a) ¨ (b) ¨

3.

SEC use only

4.

Source of funds

WC

5.

Check box if disclosure of legal proceedings is required pursuant to Item 2(e) or 2(f) ¨

6.

Citizenship or place of organization

South Korea

Number of

shares

beneficially

owned by

each

reporting

person

with

7.

Sole voting power

0

8.

Shared voting power

9,020,272*

9.

Sole dispositive power

0

10.

Shared dispositive power

9,020,272*

11.

Aggregate amount beneficially owned by each reporting person

9,020,272*

12.

Check box if the aggregate amount in Row (11) excludes certain shares ¨

13.

Percent of class represented by amount in Row (11)

16.64%**

14.

Type of reporting person

CO

* Consists of: (i) 3,028,248 Common Shares of the Issuer held by ILJIN SNT Co., Ltd. (f/k/a Cheoin Leisure Co., Ltd.) (“ILJIN SNT”); (ii) 1,259,886 Common Shares issuable to ILJIN SNT upon the exercise of outstanding warrants that are exercisable within 60 days; (iii) 4,586,605 Common Shares of the Issuer held by ILJIN Life Science; and (iv) 145,533 Common...

More